Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer

Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer

BackgroundSerplulimab has shown promising results in the treatment of extensive-stage small cell lung cancer (ES-SCLC). This study aimed to evaluate the cost-effectiveness of serplulimab combination therapy compared to chemotherapy alone in patients with ES-SCLC from the Chinese healthcare system pe...

Full description

Bibliographic Details
Main Authors: Zhiwei Zheng, Hongcai Chen, Hongfu Cai
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
serplulimab
cost-effectiveness
extensive-stage
small cell lung cancer
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1259574/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1259574/full

Similar Items